Problem

Biomedical research is slowed by fragmented, manual workflows: scientists must move among literature, datasets, scripts, software dependencies, experimental planning, and result interpretation. As the volume of biological knowledge, data, and tools has grown, the pace of discovery has slowed, while researchers spend time on repetitive execution instead of higher-order scientific reasoning. The economic pain is principally wasted researcher time and delayed discovery; Phylo says Biomni has already saved millions of research hours.

The clearest killer use case is automating complex computational biology analyses that traditionally take weeks. In a Ginkgo Bioworks case study, Biomni Lab accelerated more than 10 cell-painting and transcriptomic analyses, producing publication-quality results validated by Ginkgo scientists and reducing typical workflows from weeks to hours.

Product / Service

Phylo’s product is Biomni Lab, which it describes as the first Integrated Biology Environment: a cloud workspace where biologists orchestrate AI agents across the research workflow. Users can describe problems in natural language and have agents plan, author, execute, and document work spanning literature search, experiment design, data analysis, protein structures, reagent planning, result interpretation, and next-step recommendations, while preserving context and traceability. The system brings together hundreds of biomedical tools, databases, and software packages rather than requiring scientists to assemble each workflow manually.

The delivery model combines a free individual tier, a $100-per-month Pro plan, team subscriptions, and custom enterprise deployments. Enterprise customers can receive dedicated infrastructure, custom agents, internal data and tool integrations, flexible deployment options, SSO, role-based access controls, encryption, compliance support, and expanded compute and storage. The benefit is a more reproducible, auditable, and scalable way to turn scientific questions into working analyses and research outputs, with human scientists remaining responsible for judgment and validation.

Market

Phylo competes in the emerging market for agentic AI in biomedical research, also describable as AI-native biology or the Integrated Biology Environment category. Its closest named AI-scientist comparator in the gathered evidence is Edison Scientific’s Edison Analysis/Kosmos, while Benchling AI is an adjacent competitor in biotech R&D software because it also combines scientific data, AI models, analysis, and reporting in one interface. Phylo’s differentiation is the breadth of its biomedical workflow orchestration and its integration of specialized tools, databases, and computational infrastructure.

The company launched publicly with a $13.5 million seed round co-led by Andreessen Horowitz and Menlo Ventures’ Anthology Fund with Anthropic. Its open-source Biomni foundation had reached more than 7,000 labs and tens of thousands of scientists at launch, and Stanford later reported prototype use in more than 10,000 labs across academia and industry. Commercial traction is evidenced by the Ginkgo case study, alpha-user activity, an enterprise-grade product, and an academic-lab program, but the gathered evidence does not disclose revenue or paid-customer counts; it is best characterized as an early commercial launch with a visible subscription and enterprise monetization model rather than proven scale revenue.